ClinicalTrials.gov registry snapshot / 2026-07-24

Peptide trials,
without the maze.

Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.

268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program

Study status is not drug rank.

Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.

Official registry finder

Filter the exact records.

Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.

Reset
12matching registry records
Snapshot timestampJuly 24, 2026 at 9:00 AM UTC
Program and recordStatusPhase and enrollmentLocationsPrimary completionRegistry updateSource
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightNCT07339423 / AMAZE 1 / Novo Nordisk A/SRecruitingVerified 2026-07Phase 31,150 estimated71 recruiting72 listed / 9 countriesJun 26, 2029estimatedJul 9, 2026ClinicalTrials.govOpen NCT07339423
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07481630 / AMAZE 5 / Novo Nordisk A/SRecruitingVerified 2026-07Phase 3400 estimated73 recruiting82 listed / 10 countriesAug 14, 2028estimatedJul 9, 2026ClinicalTrials.govOpen NCT07481630
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight LossNCT07503210 / AMAZE 12 / Novo Nordisk A/SRecruitingVerified 2026-07Phase 3600 estimated67 recruiting72 listed / 12 countriesJun 6, 2028estimatedJul 9, 2026ClinicalTrials.govOpen NCT07503210
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07509307 / AMAZE 6 / Novo Nordisk A/SRecruitingVerified 2026-07Phase 3400 estimated73 recruiting81 listed / 11 countriesAug 14, 2028estimatedJul 9, 2026ClinicalTrials.govOpen NCT07509307
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNCT07533175 / AMAZE 2 / Novo Nordisk A/SRecruitingVerified 2026-07Phase 3630 estimated57 recruiting74 listed / 10 countriesAug 7, 2028estimatedJul 9, 2026ClinicalTrials.govOpen NCT07533175
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 / HF-POLARIS / Novo Nordisk A/SRecruitingVerified 2026-07Phase 35,610 estimated470 recruiting839 listed / 27 countriesJul 23, 2029estimatedJul 15, 2026ClinicalTrials.govOpen NCT07567001
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571005 / AMAZE 3 / Novo Nordisk A/SRecruitingVerified 2026-07Phase 3300 estimated55 recruiting80 listed / 10 countriesJul 12, 2028estimatedJul 13, 2026ClinicalTrials.govOpen NCT07571005
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571109 / AMAZE 4 / Novo Nordisk A/SRecruitingVerified 2026-07Phase 3300 estimated67 recruiting92 listed / 10 countriesJun 26, 2028estimatedJul 13, 2026ClinicalTrials.govOpen NCT07571109
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNCT07400107 / AMAZE 8 / Novo Nordisk A/SNot yet recruitingVerified 2026-03Phase 31,000 estimated0 recruiting120 listed / 14 countriesDec 12, 2028estimatedMar 12, 2026ClinicalTrials.govOpen NCT07400107
AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose WeightNCT07668401 / AMAZE 13 / Novo Nordisk A/SNot yet recruitingVerified 2026-07Phase 3400 estimated0 recruiting41 listed / 5 countriesJan 11, 2029estimatedJul 21, 2026ClinicalTrials.govOpen NCT07668401
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutideNCT07668414 / AMAZE 7 / Novo Nordisk A/SNot yet recruitingVerified 2026-06Phase 3650 estimated0 recruiting46 listed / 1 countriesOct 10, 2028estimatedJun 25, 2026ClinicalTrials.govOpen NCT07668414
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose WeightNCT07720271 / AMAZE 9 / Novo Nordisk A/SNot yet recruitingVerified 2026-07Phase 3950 estimated0 recruiting42 listed / 1 countriesJun 27, 2028estimatedJul 22, 2026ClinicalTrials.govOpen NCT07720271
Clinical trial finder FAQ

Status, location, and enrollment are different fields.

These answers prevent the most common registry-search errors before a reader follows an official source.

01

Are any Retatrutide clinical trials recruiting?

Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.

02

How do I find a peptide clinical trial near me?

Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.

03

Does Recruiting mean I can join the trial?

No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.

04

Are the drugs in this clinical trial finder FDA approved?

A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.

05

Why do only some registry records show posted results?

11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.

06

How current is the peptide clinical trial data?

The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.

Evidence boundary

A registry finder, not an enrollment service.

A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.

Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.

Read the official API documentation ↗Understand evidence categories →